Loading data

 

 

 

 

 

 

Columbus Breast Reconstruction Using Tissue Expander

Tissue Expander / Implant / Acellular Dermal Matrix

Breast reconstruction can also be accomplished by using prosthetic, implanted devices. With this method, the final reconstruction consists of a permanent breast implant, either silicone or saline, positioned under the skin and pectoralis muscle. Generally speaking, implant-based reconstruction can be done in multiple stages or as a single step.

Staged expander-implant

In the staged method, a device known as a tissue expander is placed at the initial operation. This can be placed at the same time as the mastectomy or at a later date, in a delayed fashion. Two to three weeks after surgery, the tissue expander is gradually inflated by adding saline to the device. This is done in the outpatient setting and continued until the expander is filled to a desired size. The main goal of this first stage is to expand the skin and create a pocket where the permanent implant will ultimately reside.

 

The second stage involves removal of the tissue expander and placement of the permanent implant. This is usually an outpatient procedure and involves less recovery time than the initial operation.

Single stage or straight-to-implant

A traditional mastectomy procedure removes the breast tissue and skin, leaving a relatively flat surface on the chest. In such cases, the staged approach with initial tissue expansion is necessary to expand skin and create a space for the permanent implant. Other mastectomy techniques, such as the skin-sparing and nipple-sparing procedures, remove mainly the breast tissue while leaving much of the skin of breast and chest intact. If an adequate amount of skin is spared, it is sometimes possible to avoid the initial expander stage and place the permanent implant at the time of mastectomy. The straight-to-implant reconstruction is only possible immediately after the mastectomy and not an option for patients seeking a delayed reconstruction.

Acellular Dermal Matrix

The tissue expander and implant method may, in some cases, require the use of a biologic implant known as acellular dermal matrix. This material is derived from the skin of either animals or cadavers and is treated to contain no living cells. Instead, it serves as a biologic scaffold, or sheet, that can be used to facilitate the reconstruction. There are several different products available such as AlloDerm (Lifecell), AlloMax (Bard), and Flex HD (Ethicon) to only name a few.

 

In both the staged and straight-to-implant methods, the prosthesis is placed under the pectoralis muscle. In its natural, uninterrupted state, the pectoralis muscle sits closely on the chest wall and there is very little space between these two structures. Additionally, the lower attachments of the pectoralis muscle to the chest wall are generally higher than the natural position of the breast crease (inframammary fold). Therefore, dividing these lower attachments can allow for improved positioning of the tissue expander or implant and more space under the muscle making it possible to accommodate a larger volume in the device. However, when it is cut, the lower part of the muscle retracts upwards and creates a gap between the muscle and the chest wall. This is where acellular dermal matrix is placed, essentially forming a bridge or sling between the lower, cut edge of the muscle and the chest wall. Once placed, the biologic material is gradually replaced by ingrowth of one’s own cells and tissue and does not need to be removed at a later date.

CONTACT US

Copyright 2014 Midwest Breast & Aesthetic Surgery. All Rights Reserved.

Powered by: Centaur Marketing

Pankaj Tiwari, MD

DEGREES

MEDICAL TRAINING

CERTIFICATIONS

LICENSURES

POSITIONS

PROFESSIONAL SOCIETY MEMBERSHIPS

HONORS AND AWARDS

INTERNATIONAL VISITING PROFESSOR

INTERNATIONAL OBSERVERSHIPS

INTERNATIONAL CHARITABLE ACTIVITIES

EDITORSHIP

COMMUNITY ACITIVITIES

PEER-REVIEWED JOURNAL ARTICLES

BOOK CHAPTERS

PRESENTATIONS (LOCAL / NATIONAL / INTERNATIONAL)

Bianca Chin, MD

DEGREES

MEDICAL TRAINING

LICENSURES

POSITIONS

PROFESSIONAL SOCIETY MEMBERSHIPS

HONORS AND AWARDS

PEER-REVIEWED JOURNAL ARTICLES

PRESENTATIONS (LOCAL / NATIONAL / INTERNATIONAL)

Ergun Kocak, MD

DEGREES

MEDICAL TRAINING

LICENSURES

POSITIONS

PROFESSIONAL SOCIETY MEMBERSHIPS

HONORS AND AWARDS

CLINICAL TRIALS

PEER-REVIEWED JOURNAL ARTICLES

PRESENTATIONS (LOCAL / NATIONAL / INTERNATIONAL)

BOOK CHAPTERS

 

Pankaj Tiwari, MD
[email protected]
Testimony
"Lizzie B. Byrd Act"
November 6, 2013

Good morning Chairwoman Jones, Vice Chair Burke, Ranking Member Cafaro and members of the Senate Medicaid, Health and Human Services Committee. Thank you for the opportunity to present Testimony on the “Lizzie B. Byrd Act.”

In May of 2011, House Bill 217 was introduced in the 129th General Assembly. This bill highlighted the fact that not all Ohio women were aware that they could obtain breast cancer reconstructive surgery at the same time they obtained a mastectomy, while having both procedures covered by insurance.

As a Reconstructive Plastic Surgeon, much of my clinical practice is focused on reconstruction after cancer. Many of my patients undergo reconstruction at the time of mastectomy for breast cancer. I would like to highlight two specific aspects of breast reconstruction based on my clinical experience. I will divide these considerations into “patient-centered” and “care management.”

“Patient-centered” – Breast reconstruction at the time of mastectomy (immediate reconstruction) allows patients to move beyond the stigmata of disease that often persist after completing mastectomy, chemotherapy and radiation treatment. It is well accepted in the medical literature that the physical deformities of treatment lead to impairment in patient quality of life. Breast reconstruction at the time of mastectomy has significantly demonstrated quality of life improvement for patients. This data results from studies using validated survey questionnaires submitted to patients who have undergone reconstruction and those who have not undergone reconstruction. Quality of life improvements include return to work and to activities of daily living as well as improvements in psychosocial outcomes such as the incidence of depression among breast cancer survivors.

“Care management” – Immediate reconstruction reduces the overall cost of care as compared to reconstruction performed at a later time point (delayed reconstruction). As part of the Women’s Health Care Act of 1998, reconstructive breast surgery after mastectomy falls under the purview of insurance coverage. Immediate reconstruction reduces the overall numbers of days spent in the hospital and the number of revisionary lifetime surgeries as compared to delayed reconstruction. Clinical evidence demonstrates that certain types of immediate reconstruction may reduce the incidence of chronic lymphedema and the attendant costs associated with lifelong management of this chronic condition. Finally, the “Lizzie B. Bird Act” presents a model for vertically integrated physician collaboration that should increasingly become the standard for Accountable Care Organizations (ACOs). Improved care coordination among the members of the healthcare team (medical oncology, surgical oncology, radiation therapy and reconstructive plastic surgery) limits the potential for errors in clinical judgment that lead to costly revisionary surgery.

In my clinical experience, information to the patient regarding her options for breast reconstruction at the time of mastectomy leads to improved care coordination and improved patient outcomes with a decreased incidence of lifetime surgery. I would be happy to provide references from the scientific literature should the committee request them.

Again, thank-you Chairwoman Jones and members of the Senate Medicaid, Health and Human Services Committee. I will be more than happy to answer any questions that you may have at this time.